Alumis Inc. Announces Strong Phase 3 Results for Envudeucitinib in Plaque Psoriasis and Reports First‑Quarter 2026 Financials

Alumis Inc. (Nasdaq: ALMS), a late‑stage biopharmaceutical company focused on targeted therapies for immune‑mediated diseases, released its financial results for the quarter ended March 31, 2026, and highlighted the outcomes of a late‑breaking oral presentation of Phase 3 data for envudeucitinib at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

Phase 3 Clinical Performance

  • Robust PASI Responses – PASI 90 achieved by 68.0 % and 62.1 % of patients at Week 24. – PASI 100 achieved by 41.0 % and 39.5 % of patients at Week 24. – Early skin‑clearance noted as early as Week 4 in more than 30 % of patients; over 75 % of patients achieved clear or almost‑clear scalp psoriasis by Week 24.

  • Quality‑of‑Life and Itch Relief – Improvements in patient‑reported quality‑of‑life measures and itch relief preceded PASI 90 clearance.

  • Safety Profile – Enforced a favorable safety and tolerability profile consistent with the Phase 2 program.

The data support envudeucitinib’s potential to reshape the psoriasis treatment landscape as a highly selective oral tyrosine‑kinase‑2 (TYK2) inhibitor.

Business Outlook

  • NDA Submission – Alumis remains on track to file a New Drug Application (NDA) in the fourth quarter of 2026.

  • Systemic Lupus Erythematosus (SLE) Pipeline

  • The company anticipates pivotal Phase 2b topline data for envudeucitinib in SLE in the third quarter of 2026.

  • Strategic Expansion – Alumis is evaluating additional indications under a unified TYK2 franchise strategy and will provide further updates later this year.

Market Reaction

  • Analyst Revision

  • Guggenheim raised its price target for Alumis stock to $34 following the psoriasis data, indicating increased confidence in the company’s prospects.

  • Stock Performance

  • As of May 13, 2026, the stock closed at $24.63, with a 52‑week high of $30.60 and a 52‑week low of $2.76.

  • The market capitalization stands at $3.16 billion.

Additional Corporate Activity

  • Alumis withdrew a potential competitive positioning against Amgen’s Tepezza after assessing the market prospects, according to a report by FierceBiotech.

Alumis continues to progress its TYK2‑based platform across multiple immune‑mediated disease indications while maintaining a clear development roadmap for envudeucitinib, its flagship oral therapy.